Comparative Pharmacology
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETHAZINE WITH CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETHAZINE WITH CODEINE.
MYMETHAZINE FORTIS vs PROMETHAZINE WITH CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
Promethazine is a phenothiazine derivative that antagonizes histamine at H1 receptors, acting as a sedative and antiemetic. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects via central nervous system depression.
50 mg orally every 6 hours as needed for nausea and vomiting.
10-20 mg promethazine and 10-20 mg codeine (based on phosphate) orally every 4-6 hours as needed for cough; maximum daily codeine dose 120 mg.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Promethazine: 9-16 hours (mean 12 hours), clinically significant for sedation duration. Codeine: 2.5-4 hours (mean 3 hours), with active metabolite morphine 2-3 hours.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Promethazine: renal 70% as metabolites and unchanged drug, biliary/fecal 20-30%. Codeine: renal 90% (5-15% unchanged, rest as morphine and conjugates), fecal <10%.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic